EpiTherapeutics is developing novel innovative cancer drugs based on the world leading research in epigenetics conducted by Professor Kristian Helin and his group at Biotech Research & Innovation Centre (BRIC) at University of Copenhagen.
EpiTherapeutics' development programs are focused on enzymes involved in the regulation of transcription in cancer – current programs target histone demethylases and methyltransferases. Subsequent developments may identify other potential clinical indications outside oncology.
EpiTherapeutics is funded by two of the leading Danish life science investor groups, Novo and SEED Capital Denmark to advance the discovery and development of new cancer treatments by leveraging breakthroughs in the field of Epigenetics.
